Last 28 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 15.23 | 7.11 | 12.73 | 24.62 | 7.92 | 11.62 | 10.64 | 10.12 | 12.66 | 37.71 | 12.53 | 17.94 | 13.00 | 15.71 | 17.01 | 17.44 | 7.69 | 31.26 | 34.75 | 28.05 | — |
| — | -38.8% | +19.7% | +143.3% | -37.4% | -69.2% | -15.1% | -43.6% | -2.7% | +140.1% | -26.3% | +2.9% | +69.1% | -49.7% | -51.1% | -37.8% | — | +6.3% | -45.3% | — | — | |
| P/S Ratio | 2.75 | 2.05 | 1.91 | 2.25 | 1.69 | 2.30 | 2.63 | 2.49 | 3.12 | 2.51 | 3.13 | 2.82 | 3.10 | 3.98 | 4.19 | 6.62 | 5.78 | 6.94 | 8.64 | 7.05 | 6.85 |
| — | -11.1% | -27.3% | -9.5% | -45.9% | -8.3% | -15.9% | -11.8% | +0.7% | -36.9% | -25.4% | -57.3% | -46.4% | -42.6% | -51.4% | -6.1% | -15.6% | +23.9% | +6.1% | -22.8% | -38.5% | |
| P/B Ratio | 2.78 | 2.14 | 1.81 | 2.52 | 1.94 | 2.39 | 2.70 | 3.04 | 3.89 | 3.22 | 3.75 | 4.07 | 4.13 | 4.41 | 4.51 | 8.43 | 7.88 | 12.05 | 13.74 | 13.79 | 14.55 |
| — | -10.3% | -32.9% | -17.0% | -50.2% | -25.9% | -28.2% | -25.3% | -5.7% | -26.8% | -16.8% | -51.7% | -47.6% | -63.4% | -67.2% | -38.9% | -45.8% | -7.8% | -23.7% | -34.8% | -32.3% | |
| P/FCF | 6.87 | 5.79 | 14.83 | 4.36 | 3.72 | 5.82 | 14.34 | 6.67 | 8.24 | 10.34 | 15.53 | 6.21 | 7.88 | 14.50 | 11.74 | 31.82 | 12.30 | 22.05 | 25.58 | 17.13 | 18.24 |
| — | -0.5% | +3.4% | -34.7% | -54.8% | -43.7% | -7.6% | +7.5% | +4.6% | -28.7% | +32.3% | -80.5% | -35.9% | -34.2% | -54.1% | +85.7% | -32.6% | -4.7% | -34.0% | -66.5% | -68.3% | |
| EV / EBITDA | 8.02 | 4.58 | 7.30 | 9.15 | 3.99 | 6.80 | 6.55 | 7.02 | 7.84 | 14.67 | 7.71 | 9.64 | 6.60 | 9.51 | 10.23 | 15.57 | 36.76 | 18.68 | 22.25 | 18.97 | 21.52 |
| — | -32.7% | +11.4% | +30.4% | -49.1% | -53.6% | -15.0% | -27.2% | +18.8% | +54.3% | -24.6% | -38.1% | -82.1% | -49.1% | -54.0% | -17.9% | +70.8% | +24.0% | -14.4% | -54.5% | -46.9% | |
| EV / EBIT | 9.00 | 4.53 | 7.36 | 9.50 | 4.23 | 6.91 | 6.68 | 7.17 | 7.98 | 15.40 | 7.96 | 8.10 | 7.92 | 10.01 | 10.93 | 17.53 | 55.22 | 22.06 | 26.45 | 253.22 | — |
| — | -34.5% | +10.1% | +32.5% | -47.0% | -55.1% | -16.1% | -11.4% | +0.7% | +53.9% | -27.1% | -53.8% | -85.7% | -54.6% | -58.7% | -93.1% | — | +21.8% | -23.1% | +288.6% | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 77.2% | 75.8% | 79.3% | 71.9% | 75.1% | 81.0% | 82.7% | 73.0% | 77.0% | 81.4% | 82.2% | 74.4% | 79.8% | 81.4% | 82.6% | 79.0% | 80.4% | 82.3% | 82.8% | 80.5% | 81.9% |
| — | -6.4% | -4.0% | -1.5% | -2.5% | -0.5% | +0.6% | -1.9% | -3.6% | +0.0% | -0.4% | -5.9% | -0.7% | -1.2% | -0.2% | -1.8% | -1.8% | -0.6% | +0.2% | -2.3% | -1.0% | |
| Operating Margin | 24.0% | 34.2% | 17.3% | 15.8% | 27.3% | 24.0% | 30.4% | 27.7% | 33.2% | 12.4% | 33.7% | 23.9% | 40.3% | 34.9% | 33.9% | 37.1% | 10.2% | 30.9% | 32.3% | 31.4% | 26.1% |
| — | +42.2% | -43.1% | -42.9% | -17.6% | +94.5% | -9.5% | +16.0% | -17.6% | -64.6% | -0.8% | -35.7% | +296.4% | +12.9% | +5.1% | +18.2% | -61.1% | -2.0% | +32.6% | +127.7% | +14.6% | |
| Net Margin | 18.3% | 28.9% | 15.1% | 9.2% | 21.2% | 19.8% | 24.7% | 24.6% | 24.8% | 6.7% | 24.8% | 15.8% | 24.0% | 25.6% | 24.8% | 37.8% | 75.0% | 22.0% | 25.2% | 24.9% | -11.9% |
| — | +45.5% | -38.8% | -62.5% | -14.3% | +195.8% | -0.5% | +55.6% | +3.2% | -73.8% | +0.2% | -58.2% | -68.0% | +16.2% | -1.7% | +51.8% | +729.7% | +15.0% | +103.5% | +6839.4% | -384.7% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 20.8% | 7.9% | 3.6% | 2.6% | 6.3% | 5.3% | 6.6% | 7.9% | 8.1% | 2.2% | 7.8% | 5.6% | 8.0% | 7.4% | 7.0% | 13.0% | 29.8% | 10.2% | 10.7% | 13.4% | -6.9% |
| — | +48.3% | -44.7% | -66.5% | -22.1% | +142.2% | -15.4% | +40.4% | +2.0% | -70.2% | +11.9% | -56.8% | -73.3% | -27.6% | -34.9% | -3.2% | +531.3% | -15.2% | +48.7% | +6284.1% | -181.8% | |
| ROA | 14.0% | 5.7% | 2.6% | 1.8% | 4.4% | 3.7% | 4.4% | 5.1% | 5.2% | 1.4% | 4.6% | 3.3% | 5.0% | 4.7% | 4.2% | 7.4% | 15.3% | 4.9% | 4.8% | 5.5% | -2.6% |
| — | +55.1% | -42.4% | -64.7% | -14.9% | +170.5% | -4.1% | +53.3% | +3.2% | -70.8% | +8.9% | -54.5% | -67.3% | -4.3% | -11.3% | +33.7% | +697.6% | +19.9% | +147.7% | +9991.4% | -428.2% | |
| ROIC | 42.0% | 11.8% | 6.3% | 8.1% | 13.0% | 8.9% | 10.6% | 10.7% | 11.5% | 4.1% | 10.7% | 8.5% | 13.5% | 9.9% | 8.7% | 11.4% | 3.7% | 12.9% | 12.5% | 14.2% | 10.0% |
| — | +32.7% | -40.3% | -24.3% | +12.7% | +119.0% | -1.4% | +25.5% | -14.7% | -59.0% | +23.5% | -25.5% | +259.4% | -23.3% | -30.6% | -19.6% | -62.4% | +20.0% | +29.0% | +56.8% | -15.2% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.28 | 0.15 | 0.23 | 0.28 | 0.20 | 0.22 | 0.25 | 0.28 | 0.31 | 0.35 | 0.37 | 0.42 | 0.41 | 0.40 | 0.43 | 0.48 | 0.56 | 0.78 | 0.89 | 1.05 | 1.26 |
| — | -31.3% | -7.9% | +0.0% | -34.5% | -36.1% | -34.2% | -34.5% | -25.2% | -12.1% | -13.4% | -11.7% | -25.6% | -48.7% | -51.7% | -54.7% | -55.9% | -49.7% | -50.5% | -47.5% | -38.1% | |
| Debt / EBITDA | 1.02 | 1.62 | 4.77 | 5.21 | 2.38 | 3.20 | 2.85 | 2.94 | 2.74 | 6.90 | 3.32 | 4.23 | 2.83 | 3.66 | 4.12 | 3.57 | 10.67 | 4.90 | 5.86 | 5.86 | 7.47 |
| — | -49.5% | +67.4% | +77.2% | -13.2% | -53.6% | -14.1% | -30.5% | -3.2% | +88.6% | -19.4% | +18.6% | -73.5% | -25.3% | -29.7% | -39.1% | +42.9% | -29.8% | -42.3% | -63.4% | -52.2% | |
| Current Ratio | 3.60 | 3.48 | 3.58 | 3.60 | 3.75 | 3.84 | 3.67 | 3.31 | 3.24 | 3.13 | 3.11 | 2.75 | 4.12 | 4.90 | 4.90 | 5.07 | 3.56 | 4.91 | 4.96 | 5.29 | 5.05 |
| — | -9.4% | -2.4% | +8.7% | +15.9% | +22.7% | +18.1% | +20.1% | -21.4% | -36.1% | -36.5% | -45.7% | +15.7% | -0.2% | -1.2% | -4.1% | -29.6% | -12.3% | -6.7% | +170.7% | -35.8% | |
| Quick Ratio | 3.58 | 3.45 | 3.56 | 3.58 | 3.72 | 3.80 | 3.63 | 3.27 | 3.20 | 3.09 | 3.07 | 2.72 | 4.07 | 4.84 | 4.85 | 5.02 | 3.52 | 4.84 | 4.88 | 5.21 | 4.95 |
| — | -9.3% | -2.1% | +9.5% | +16.5% | +23.2% | +18.3% | +20.1% | -21.5% | -36.3% | -36.7% | -45.8% | +15.6% | +0.0% | -0.5% | -3.6% | -28.9% | -11.3% | -5.9% | +170.4% | -36.5% | |
| Interest Coverage | 15.68 | 31.28 | 13.27 | 12.49 | 18.64 | 14.61 | 15.91 | 14.34 | 15.30 | 5.93 | 12.42 | 11.49 | 8.39 | 8.09 | 7.59 | 13.31 | 3.00 | 8.44 | 6.61 | 0.60 | -0.94 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 28 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying HRMY stock.
Harmony Biosciences Holdings, Inc.'s current P/E is 15.2x. The average P/E over the last 4 quarters is 13.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Harmony Biosciences Holdings, Inc.'s current operating margin is 24.0%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Harmony Biosciences Holdings, Inc.'s business trajectory between earnings reports.